{"pmid":32324898,"title":"Incidence of Adverse Drug Reactions in COVID-19 patients in China: an active monitoring study by Hospital Pharmacovigilance System.","text":["Incidence of Adverse Drug Reactions in COVID-19 patients in China: an active monitoring study by Hospital Pharmacovigilance System.","To evaluate the incidence, type and risk factors associated with adverse drug reactions (ADRs) among COVID-19 patients by Hospital Pharmacovigilance System (CHPS). A retrospective analysis was performed on 217 COVID-19 patients admitted to the First Hospital of Changsha in China, from January 17, 2020 to February 29, 2020. The active monitoring model in CHPS was used to detect ADR signals of hospital information system. The risk factors for the ADRs were classified using the WHO-UMC system. Univariate and multivariate logistic regression was carried out to analyze the risk factors of ADRs. Our results showed that the prevalence of ADRs was 37.8% in the patients, which was predominated by drug-induced gastrointestinal disorders and liver system disorders (23.0% vs. 13.8% ). The ADR could be explained by the use of lopinavir/ ritonavir and umifenovir by 63.8% and 18.1%, respectively. 96.8% of ADRs occurred within 14 days of hospitalization. Multivariable analysis showed that length of stay (OR: 2.02, [95% CI: 1.03-3.96], P=0.04), number of drugs used in hospital (OR: 3.17, [95%CI: 1.60-6.27], P=0.001) and underlying basic diseases (OR:2.07, [95%CI: 1.02-4.23], P = 0.04) were independent risk factor for ADRs in the patients. Together, the incidence of ADRs was significantly high during the treatment period. Moreover, the active monitoring of the CHPS system reflected ADRs during COVID-19 treatment in the real world, which provided reference for safe medication in clinic.","Clin Pharmacol Ther","Sun, Ji","Deng, Xuanyu","Chen, Xiaoping","Huang, Juanjuan","Huang, Siqiong","Li, Yanfei","Feng, Jinhui","Liu, Jiyang","He, Gefei","32324898"],"abstract":["To evaluate the incidence, type and risk factors associated with adverse drug reactions (ADRs) among COVID-19 patients by Hospital Pharmacovigilance System (CHPS). A retrospective analysis was performed on 217 COVID-19 patients admitted to the First Hospital of Changsha in China, from January 17, 2020 to February 29, 2020. The active monitoring model in CHPS was used to detect ADR signals of hospital information system. The risk factors for the ADRs were classified using the WHO-UMC system. Univariate and multivariate logistic regression was carried out to analyze the risk factors of ADRs. Our results showed that the prevalence of ADRs was 37.8% in the patients, which was predominated by drug-induced gastrointestinal disorders and liver system disorders (23.0% vs. 13.8% ). The ADR could be explained by the use of lopinavir/ ritonavir and umifenovir by 63.8% and 18.1%, respectively. 96.8% of ADRs occurred within 14 days of hospitalization. Multivariable analysis showed that length of stay (OR: 2.02, [95% CI: 1.03-3.96], P=0.04), number of drugs used in hospital (OR: 3.17, [95%CI: 1.60-6.27], P=0.001) and underlying basic diseases (OR:2.07, [95%CI: 1.02-4.23], P = 0.04) were independent risk factor for ADRs in the patients. Together, the incidence of ADRs was significantly high during the treatment period. Moreover, the active monitoring of the CHPS system reflected ADRs during COVID-19 treatment in the real world, which provided reference for safe medication in clinic."],"journal":"Clin Pharmacol Ther","authors":["Sun, Ji","Deng, Xuanyu","Chen, Xiaoping","Huang, Juanjuan","Huang, Siqiong","Li, Yanfei","Feng, Jinhui","Liu, Jiyang","He, Gefei"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324898","week":"202017|Apr 20 - Apr 26","doi":"10.1002/cpt.1866","keywords":["adverse drug reactions","chps","covid-19","active monitoring"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["China","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664895932833988608,"score":8.518259,"similar":[{"pmid":32321905,"title":"Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.","text":["Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.","In late March and early April 2020, the antimalarial drug, chloroquine, has been approved as an emergency treatment for the coronavirus disease 2019 (COVID-19) in the United States and in Europe. Although infrequent, neuropsychiatric symptoms have been reported in patients who received chloroquine for the treatment of malaria or autoimmune diseases. In this study, aiming to investigate these adverse events (AEs) using a large self-reporting database, we conducted a disproportionality analysis for the detection of neuropsychiatric AE signals associated with the use of chloroquine (or hydroxychloroquine), reported to FDA Adverse Event Reporting System (FAERS) database between the fourth quarter of 2012 and the fourth quarter of 2019. We included 2,389,474 AE cases, among which 520 cases developed neuropsychiatric AE following the use of chloroquine. Adjusted reporting odds ratio (ROR) for the development of each of the neuropsychiatric AEs following the use of chloroquine was calculated using a multilevel model: exposure to chloroquine was associated with a statistically significant high reporting of amnesia, delirium, hallucinations, depression, and loss of consciousness, (lower 95% confidence interval of the adjusted ROR > 1), although the degree of increase in their ROR was limited. There was no statistically significant high reporting of any other neuropsychiatric AE, including suicide, psychosis, confusion, and agitation. Current pharmacovigilance study results did not suggest any potential link between the use of chloroquine and an increased risk of suicide, psychosis, confusion, and agitation, which would be informative during the emergency use of chloroquine for the treatment of COVID-19.","Biosci Trends","Sato, Kenichiro","Mano, Tatsuo","Iwata, Atsushi","Toda, Tatsushi","32321905"],"abstract":["In late March and early April 2020, the antimalarial drug, chloroquine, has been approved as an emergency treatment for the coronavirus disease 2019 (COVID-19) in the United States and in Europe. Although infrequent, neuropsychiatric symptoms have been reported in patients who received chloroquine for the treatment of malaria or autoimmune diseases. In this study, aiming to investigate these adverse events (AEs) using a large self-reporting database, we conducted a disproportionality analysis for the detection of neuropsychiatric AE signals associated with the use of chloroquine (or hydroxychloroquine), reported to FDA Adverse Event Reporting System (FAERS) database between the fourth quarter of 2012 and the fourth quarter of 2019. We included 2,389,474 AE cases, among which 520 cases developed neuropsychiatric AE following the use of chloroquine. Adjusted reporting odds ratio (ROR) for the development of each of the neuropsychiatric AEs following the use of chloroquine was calculated using a multilevel model: exposure to chloroquine was associated with a statistically significant high reporting of amnesia, delirium, hallucinations, depression, and loss of consciousness, (lower 95% confidence interval of the adjusted ROR > 1), although the degree of increase in their ROR was limited. There was no statistically significant high reporting of any other neuropsychiatric AE, including suicide, psychosis, confusion, and agitation. Current pharmacovigilance study results did not suggest any potential link between the use of chloroquine and an increased risk of suicide, psychosis, confusion, and agitation, which would be informative during the emergency use of chloroquine for the treatment of COVID-19."],"journal":"Biosci Trends","authors":["Sato, Kenichiro","Mano, Tatsuo","Iwata, Atsushi","Toda, Tatsushi"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32321905","week":"202017|Apr 20 - Apr 26","doi":"10.5582/bst.2020.03082","keywords":["covid-19","faers","adverse events","chloroquine","pharmacovigilance","real-world data"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["United States","amnesia"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Hydroxychloroquine","Chloroquine"],"_version_":1664895932840280064,"score":308.8652},{"pmid":32271369,"title":"Prediction for Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score.","text":["Prediction for Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score.","BACKGROUND: We aimed to clarify the high-risk factors with multivariate analysis and establish a prediction of disease progression, so as to help clinicians to better choose therapeutic strategy. METHODS: All the consecutive patients with COVID-19 admitted to Fuyang second people's hospital or the fifth medical center of Chinese PLA general hospital between January 20 and February 22, 2020, were enrolled and their clinical data were retrospectively collected. Multivariate COX regression was used to identify the risk factors associated with progression, and then were incorporated into the nomogram to establish a novel prediction scoring model. ROC was used to assess the performance of the novel model. RESULTS: Overall, 208 patients were divided into stable group (n=168, 80.8%) and progressive group (n=40,19.2%) based on whether their conditions worsened during the hospitalization Univariate and multivariate analysis showed that comorbidity, older age, lower lymphocyte and higher lactate dehydrogenase at presentation were independent high-risk factors for COVID-19 progression. Incorporating these 4 factors, the nomogram achieved good concordance indexes of 0.86 (95%CI 0.81 - 0.91), and had well-fitted calibration curves. A novel scoring model, named as CALL, was established, and its area under ROC was 0.91 (95% CI 0.86 to 0.94). Using a cutoff value of 6 points, the positive and negative predictive values were 50.7% (38.9% - 62.4%) and 98.5% (94.7% - 99.8%), respectively. CONCLUSION: Using the CALL score model, clinicians can improve the therapeutic effect and reduce the mortality of COVID-19 with more accurate and reasonable resolutions on medical resources.","Clin Infect Dis","Ji, Dong","Zhang, Dawei","Xu, Jing","Chen, Zhu","Yang, Tieniu","Zhao, Peng","Chen, Guofeng","Cheng, Gregory","Wang, Yudong","Bi, Jingfeng","Tan, Lin","Lau, George","Qin, Enqiang","32271369"],"abstract":["BACKGROUND: We aimed to clarify the high-risk factors with multivariate analysis and establish a prediction of disease progression, so as to help clinicians to better choose therapeutic strategy. METHODS: All the consecutive patients with COVID-19 admitted to Fuyang second people's hospital or the fifth medical center of Chinese PLA general hospital between January 20 and February 22, 2020, were enrolled and their clinical data were retrospectively collected. Multivariate COX regression was used to identify the risk factors associated with progression, and then were incorporated into the nomogram to establish a novel prediction scoring model. ROC was used to assess the performance of the novel model. RESULTS: Overall, 208 patients were divided into stable group (n=168, 80.8%) and progressive group (n=40,19.2%) based on whether their conditions worsened during the hospitalization Univariate and multivariate analysis showed that comorbidity, older age, lower lymphocyte and higher lactate dehydrogenase at presentation were independent high-risk factors for COVID-19 progression. Incorporating these 4 factors, the nomogram achieved good concordance indexes of 0.86 (95%CI 0.81 - 0.91), and had well-fitted calibration curves. A novel scoring model, named as CALL, was established, and its area under ROC was 0.91 (95% CI 0.86 to 0.94). Using a cutoff value of 6 points, the positive and negative predictive values were 50.7% (38.9% - 62.4%) and 98.5% (94.7% - 99.8%), respectively. CONCLUSION: Using the CALL score model, clinicians can improve the therapeutic effect and reduce the mortality of COVID-19 with more accurate and reasonable resolutions on medical resources."],"journal":"Clin Infect Dis","authors":["Ji, Dong","Zhang, Dawei","Xu, Jing","Chen, Zhu","Yang, Tieniu","Zhao, Peng","Chen, Guofeng","Cheng, Gregory","Wang, Yudong","Bi, Jingfeng","Tan, Lin","Lau, George","Qin, Enqiang"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32271369","week":"202015|Apr 06 - Apr 12","doi":"10.1093/cid/ciaa414","keywords":["covid-19","coronavirus","nomogram","prediction"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664637315751870464,"score":298.31705},{"pmid":32283162,"title":"Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19.","text":["Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19.","BACKGROUND: Several studies have described the clinical characteristics of patients with novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19), indicating severe patients tended to have higher neutrophil to lymphocyte ratio (NLR). Whether baseline NLR could be an independent predictor of in-hospital death in Chinese COVID-19 patients remains to be investigated. METHODS: A cohort of patients with COVID-19 admitted to the Zhongnan Hospital of Wuhan University from January 1 to February 29 was retrospectively analyzed. The baseline data of laboratory examinations, including NLR were collected. Univariate and multivariate logistic regression models were developed to assess the independent relationship between the baseline NLR and in-hospital all-cause death. A sensitivity analysis was performed by converting NLR from a continuous variable to a categorical variable according to tertile. Interaction and stratified analyses were conducted as well. RESULTS: 245 COVID-19 patients were included in the final analyses, and the in-hospital mortality was 13.47%. Multivariate analysis demonstrated that there was 8% higher risk of in-hospital mortality for each unit increase in NLR (Odds ratio [OR]=1.08; 95% confidence interval [95% CI], 1.01 to 1.14; P=0.0147). Compared with patients in the lowest tertile, the NLR of patients in the highest tertile had a 15.04-fold higher risk of death (OR=16.04; 95% CI, 1.14 to 224.95; P=0.0395) after adjustment for potential confounders. Notably, the fully adjusted OR for mortality was 1.10 in males for each unit increase of NLR (OR=1.10; 95% CI, 1.02 to 1.19; P=0.016). CONCLUSIONS: NLR is an independent risk factor of the in-hospital mortality for COVID-19 patients especially for male. Assessment of NLR may help identify high risk individuals with COVID-19.","J Infect","Liu, Yuwei","Du, Xuebei","Chen, Jing","Jin, Yalei","Peng, Li","Wang, Harry H X","Luo, Mingqi","Chen, Ling","Zhao, Yan","32283162"],"abstract":["BACKGROUND: Several studies have described the clinical characteristics of patients with novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19), indicating severe patients tended to have higher neutrophil to lymphocyte ratio (NLR). Whether baseline NLR could be an independent predictor of in-hospital death in Chinese COVID-19 patients remains to be investigated. METHODS: A cohort of patients with COVID-19 admitted to the Zhongnan Hospital of Wuhan University from January 1 to February 29 was retrospectively analyzed. The baseline data of laboratory examinations, including NLR were collected. Univariate and multivariate logistic regression models were developed to assess the independent relationship between the baseline NLR and in-hospital all-cause death. A sensitivity analysis was performed by converting NLR from a continuous variable to a categorical variable according to tertile. Interaction and stratified analyses were conducted as well. RESULTS: 245 COVID-19 patients were included in the final analyses, and the in-hospital mortality was 13.47%. Multivariate analysis demonstrated that there was 8% higher risk of in-hospital mortality for each unit increase in NLR (Odds ratio [OR]=1.08; 95% confidence interval [95% CI], 1.01 to 1.14; P=0.0147). Compared with patients in the lowest tertile, the NLR of patients in the highest tertile had a 15.04-fold higher risk of death (OR=16.04; 95% CI, 1.14 to 224.95; P=0.0395) after adjustment for potential confounders. Notably, the fully adjusted OR for mortality was 1.10 in males for each unit increase of NLR (OR=1.10; 95% CI, 1.02 to 1.19; P=0.016). CONCLUSIONS: NLR is an independent risk factor of the in-hospital mortality for COVID-19 patients especially for male. Assessment of NLR may help identify high risk individuals with COVID-19."],"journal":"J Infect","authors":["Liu, Yuwei","Du, Xuebei","Chen, Jing","Jin, Yalei","Peng, Li","Wang, Harry H X","Luo, Mingqi","Chen, Ling","Zhao, Yan"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283162","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jinf.2020.04.002","keywords":["covid-19","mortality","neutrophil-to-lymphocyte ratio","risk factors"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664636704033603585,"score":293.81693},{"pmid":32304745,"pmcid":"PMC7159868","title":"Risk factors for disease severity, unimprovement, and mortality of COVID-19 patients in Wuhan, China.","text":["Risk factors for disease severity, unimprovement, and mortality of COVID-19 patients in Wuhan, China.","OBJECTIVE: Since December 2019, coronavirus disease (COVID-19) emerged in Wuhan. However, the characteristics and risk factors associated with disease severity, unimprovement and mortality are unclear. METHODS: All consecutive patients diagnosed with COVID-19 admitted to the Renmin Hospital of Wuhan University from January 11 to February 6, 2020 were enrolled in this retrospective cohort study. RESULTS: A total of 663 COVID-19 patients were included in this study. Among those, 247 (37.3%) had at least one kind of chronic disease. A total of 0.5% (n=3) of patients were diagnosed with mild COVID-19, while 37.8% (251/663), 47.5% (315/663), and 14.2% (94/663) were in moderate, severe, and critical condition, respectively. In our hospital during follow-up, 251 of 663 (37.9%) patients were improved and 25 patients died, leading to a mortality rate of 3.77%. Older patients (>60 years old) and those with chronic diseases were prone to have severe and critical COVID-19 conditions, show unimprovement, and die (P < 0.001, < 0.001). Multivariate logistic regression analysis identified being male (OR = 0.486, 95% CI 0.311-0.758; P = 0.001), having severe COVID-19 conditions (OR = 0.129, 95% CI 0.082-0.201; P < 0.001), expectoration (OR = 1.796, 95% CI 1.062-3.036; P = 0.029), muscle ache (OR = 0.309, 95% CI 0.153-0.626; P = 0.001), and decreased albumin (OR = 1.929, 95% CI 1.199-3.104; P = 0.007) were associated with unimprovement in COVID-19 patients. CONCLUSION: Being male, in severe COVID-19 conditions, expectoration, muscle ache, and decreased albumin were independent risk factors which influence the improvement of COVID-19 patients.","Clin Microbiol Infect","Zhang, Jixiang","Wang, Xiaoli","Jia, Xuemei","Li, Jiao","Hu, Ke","Chen, Guozhong","Wei, Jie","Gong, Zuojiong","Zhou, Chenliang","Yu, Hongang","Yu, Mosheng","Lei, Hongbo","Cheng, Fan","Zhang, Binghong","Xu, Yu","Wang, Gaohua","Dong, Weiguo","32304745"],"abstract":["OBJECTIVE: Since December 2019, coronavirus disease (COVID-19) emerged in Wuhan. However, the characteristics and risk factors associated with disease severity, unimprovement and mortality are unclear. METHODS: All consecutive patients diagnosed with COVID-19 admitted to the Renmin Hospital of Wuhan University from January 11 to February 6, 2020 were enrolled in this retrospective cohort study. RESULTS: A total of 663 COVID-19 patients were included in this study. Among those, 247 (37.3%) had at least one kind of chronic disease. A total of 0.5% (n=3) of patients were diagnosed with mild COVID-19, while 37.8% (251/663), 47.5% (315/663), and 14.2% (94/663) were in moderate, severe, and critical condition, respectively. In our hospital during follow-up, 251 of 663 (37.9%) patients were improved and 25 patients died, leading to a mortality rate of 3.77%. Older patients (>60 years old) and those with chronic diseases were prone to have severe and critical COVID-19 conditions, show unimprovement, and die (P < 0.001, < 0.001). Multivariate logistic regression analysis identified being male (OR = 0.486, 95% CI 0.311-0.758; P = 0.001), having severe COVID-19 conditions (OR = 0.129, 95% CI 0.082-0.201; P < 0.001), expectoration (OR = 1.796, 95% CI 1.062-3.036; P = 0.029), muscle ache (OR = 0.309, 95% CI 0.153-0.626; P = 0.001), and decreased albumin (OR = 1.929, 95% CI 1.199-3.104; P = 0.007) were associated with unimprovement in COVID-19 patients. CONCLUSION: Being male, in severe COVID-19 conditions, expectoration, muscle ache, and decreased albumin were independent risk factors which influence the improvement of COVID-19 patients."],"journal":"Clin Microbiol Infect","authors":["Zhang, Jixiang","Wang, Xiaoli","Jia, Xuemei","Li, Jiao","Hu, Ke","Chen, Guozhong","Wei, Jie","Gong, Zuojiong","Zhou, Chenliang","Yu, Hongang","Yu, Mosheng","Lei, Hongbo","Cheng, Fan","Zhang, Binghong","Xu, Yu","Wang, Gaohua","Dong, Weiguo"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304745","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.cmi.2020.04.012","source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Wuhan","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664632934595821570,"score":281.149},{"pmid":32304772,"pmcid":"PMC7158802","title":"Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China.","text":["Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China.","BACKGROUND: The novel coronavirus disease 2019 (COVID-19) has become a global health emergency. Cumulative number of new confirmed case and death are still increasing out of China. However, the independent predicted factors associated with the fatal outcome remain uncertain. METHODS: A retrospective cohort of 1590 hospitalized subjects with COVID-19 throughout China was established. The prognostic effects of variables, including clinical features and laboratory findings, were analyzed using Kapla-Meier method and Cox proportional hazard model. A prognostic nomogram was formulated to predict the survival of patient with COVID-19. RESULTS: In this nationwide cohort, non-survivors showed higher incidence of elderly people, subjects with co-existing chronic illness, dyspnea and laboratory abnormalities on admission, compared with survivors. Multivariate Cox regression analysis showed that age>/=75 (HR: 7.86, 95% CI: 2.44-25.35), age between 65-74 years (HR:3.43, 95%CI: 1.24-9.5), coronary heart disease (HR:4.28, 95%CI:1.14-16.13), cerebrovascular disease(HR:3.1, 95%CI:1.07-8.94), dyspnea (HR: 3.96, 95%CI:1.42-11), procalcitonin>0.5ng/ml(HR:8.72, 95%CI:3.42-22.28), aspartate aminotransferase>40U/liter (HR: 2.2, 95% CI: 1.1- 6.73) were independent risk factors associated with fatal outcome. A nomogram was established based on the results of multivariate analysis. The internal bootstrap resampling approach suggested the nomogram has sufficient discriminatory power with the C-index of 0.91 (95%CI 0.85-0.97). The calibration plots also demonstrated good consistence between the prediction and the observation. CONCLUSIONS: The proposed nomogram accurately predict clinical outcomes of patients with COVID-19 based on individual characteristics. Earlier identification, more intensive surveillance and appropriate therapy should be considered in patients with high risk.","Chest","Chen, Ruchong","Liang, Wenhua","Jiang, Mei","Guan, Weijie","Zhan, Chen","Wang, Tao","Tang, Chunli","Sang, Ling","Liu, Jiaxing","Ni, Zhengyi","Hu, Yu","Liu, Lei","Shan, Hong","Lei, Chunliang","Peng, Yixiang","Wei, Li","Liu, Yong","Hu, Yahua","Peng, Peng","Wang, Jianming","Liu, Jiyang","Chen, Zhong","Li, Gang","Zheng, Zhijian","Qiu, Shaoqin","Luo, Jie","Ye, Changjiang","Zhu, Shaoyong","Liu, Xiaoqing","Cheng, Linling","Ye, Feng","Zheng, Jinping","Zhang, Nuofu","Li, Yimin","He, Jianxing","Li, Shiyue","Zhong, Nanshan","32304772"],"abstract":["BACKGROUND: The novel coronavirus disease 2019 (COVID-19) has become a global health emergency. Cumulative number of new confirmed case and death are still increasing out of China. However, the independent predicted factors associated with the fatal outcome remain uncertain. METHODS: A retrospective cohort of 1590 hospitalized subjects with COVID-19 throughout China was established. The prognostic effects of variables, including clinical features and laboratory findings, were analyzed using Kapla-Meier method and Cox proportional hazard model. A prognostic nomogram was formulated to predict the survival of patient with COVID-19. RESULTS: In this nationwide cohort, non-survivors showed higher incidence of elderly people, subjects with co-existing chronic illness, dyspnea and laboratory abnormalities on admission, compared with survivors. Multivariate Cox regression analysis showed that age>/=75 (HR: 7.86, 95% CI: 2.44-25.35), age between 65-74 years (HR:3.43, 95%CI: 1.24-9.5), coronary heart disease (HR:4.28, 95%CI:1.14-16.13), cerebrovascular disease(HR:3.1, 95%CI:1.07-8.94), dyspnea (HR: 3.96, 95%CI:1.42-11), procalcitonin>0.5ng/ml(HR:8.72, 95%CI:3.42-22.28), aspartate aminotransferase>40U/liter (HR: 2.2, 95% CI: 1.1- 6.73) were independent risk factors associated with fatal outcome. A nomogram was established based on the results of multivariate analysis. The internal bootstrap resampling approach suggested the nomogram has sufficient discriminatory power with the C-index of 0.91 (95%CI 0.85-0.97). The calibration plots also demonstrated good consistence between the prediction and the observation. CONCLUSIONS: The proposed nomogram accurately predict clinical outcomes of patients with COVID-19 based on individual characteristics. Earlier identification, more intensive surveillance and appropriate therapy should be considered in patients with high risk."],"journal":"Chest","authors":["Chen, Ruchong","Liang, Wenhua","Jiang, Mei","Guan, Weijie","Zhan, Chen","Wang, Tao","Tang, Chunli","Sang, Ling","Liu, Jiaxing","Ni, Zhengyi","Hu, Yu","Liu, Lei","Shan, Hong","Lei, Chunliang","Peng, Yixiang","Wei, Li","Liu, Yong","Hu, Yahua","Peng, Peng","Wang, Jianming","Liu, Jiyang","Chen, Zhong","Li, Gang","Zheng, Zhijian","Qiu, Shaoqin","Luo, Jie","Ye, Changjiang","Zhu, Shaoyong","Liu, Xiaoqing","Cheng, Linling","Ye, Feng","Zheng, Jinping","Zhang, Nuofu","Li, Yimin","He, Jianxing","Li, Shiyue","Zhong, Nanshan"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304772","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.chest.2020.04.010","keywords":["covid-19","fatal outcome","nomogram","risk factors"],"source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"locations":["China","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664632934650347520,"score":277.49728}]}